A systematic review and meta-analysis showed that DM was a significant risk factor in development of pancreatic and gastric NETs among all case–control studies examined, and the overall risk was greater in patients with DM who were receiving insulin [15,30]. Here, INS is linked to gastric neuroendocrine tumor, well differentiated, low or intermediate grade.